Designated Standards for UK Medical Devices
Updated: 2026-11-12 · GRZAN Regulatory Team · Verification date 2026-10-20
1. Key takeaways
The UK has replaced the EU concept of harmonised standards with the designated standard system, whose legal basis is UK MDR 2002 reg 3A. Conformity with a designated standard provides a presumption of conformity with the corresponding essential requirements. Because the UK and EU standard lists have progressively diverged, manufacturers must verify that each standard they rely on is on the current UK designated list, rather than relying on its status as an EU harmonised standard. This is a change of mindset as much as of procedure. Under the pre-Brexit regime, a single European standard list served both markets, and a standard’s citation in a technical file could be verified once. Under the separated regime, the same standard number may carry different legal weight on each side of the Channel, and its status can change independently in each jurisdiction. The sections below explain what the presumption does and does not provide, how the list divergence works in practice, and how standard changes feed back into the technical documentation, along with the matrix column GRZAN recommends adding so that standard status is checked routinely instead of remembered occasionally. The sections below explain the presumption’s limits, the mechanics of list divergence and the file-update consequences of standard changes.
2. Legal basis
- UK MDR 2002 (SI 2002/618, as amended): reg 3A (designated standards), reg 8 and reg 9 (the relevant essential requirements and the assessment of conformity) and Schedule 2A.
- The Medical Devices (Amendment) (Great Britain) Regulations 2023 (SI 2023/627, made 9 June 2023): made under the Medicines and Medical Devices Act 2021, sections 15, 16, 17 and 43.
3. Expert insights
Insight one: designated standards provide a presumption, not an exemption. Conformity with a designated standard creates a presumption of conformity with the corresponding essential requirements, but the manufacturer remains responsible for overall conformity. Moreover, applying a standard is only one of the assessment routes provided by reg 9; it is not the only one. The presumption is therefore best understood as an evidential shortcut with conditions attached: the correct standard, the correct version, correctly applied to the specific device. A manufacturer who cites a designated standard without demonstrating how its clauses were applied gains nothing from the presumption if the underlying application is questioned, because the presumption attaches to the standard’s proper use rather than to its mere mention. GRZAN recommends pairing each standard citation with a short statement of which clauses were applied, so the presumption can be defended without reconstructing the reasoning later.
Insight two: list divergence is an ongoing process. The UK designated standard list and the EU harmonised standard list are maintained by different bodies and updated through different procedures. A standard that remains a harmonised standard in the EU is not necessarily still designated in the UK, and the reverse holds equally. Versions and effective dates must be checked item by item. GRZAN emphasises that this is not a one-time migration exercise. The two lists continue to evolve on independent schedules, so a mapping that was accurate last year may be wrong today. The only durable control is a periodic recheck of every standard the technical documentation relies upon, recorded with the date of verification so that the freshness of the check is itself auditable. Where a needed standard is designated in one jurisdiction but not the other, the file should say so explicitly rather than relying on a single list reference.
Insight three: standard changes feed back into the technical documentation. When a standard the documentation relies upon is superseded by a new edition or withdrawn from the designated list, the conformity arguments built on it in the technical documentation need updating. GRZAN recommends adding this to the annual documentation review checklist. The practical risk is quiet staleness: a file that was fully compliant when written can drift out of alignment as lists change around it, without any single event flagging the drift. An annual review that explicitly asks which standards changed during the year converts that hidden risk into a managed one, and pairs naturally with the update rhythm established for PMS and essential requirements reviews. Superseded editions should be marked as such in the file, with the replacement standard and its designated status recorded beside them.
4. Practical recommendations
GRZAN recommends adding a dedicated column to the essential requirements mapping matrix: the standards relied upon and their UK designated status. For each entry, record the standard number, the version, whether it is currently a designated standard in the UK, and the date of the check. GRZAN suggests reviewing this column once a year, synchronised with the annual update of the technical documentation, so that the two exercises share evidence and effort. For newly issued editions of standards, the review should assess the transition arrangements and whether revalidation is needed before the file adopts the new version. Handled this way, standard changes become a scheduled input to document control rather than a surprise, and the matrix remains a trustworthy index of the file’s evidential foundations. For devices with long lifecycles, GRZAN suggests assigning the annual standard review to the same owner as the essential requirements matrix, so both exercises stay synchronised.
5. Verification checklist
- □ A list of the standards relied upon exists
- □ UK designated status has been verified item by item, not just EU harmonised status
- □ Standard versions and verification dates are recorded
- □ A process exists for updating the technical documentation when standards change
- □ The mapping matrix includes a standard status column and is reviewed annually
Regulatory information verified as of 29 October 2026.
GRZAN supports manufacturers entering the UK market with the preparation and maintenance of registration documentation and conformity documentation. Our services for the UK market include:
- UK Responsible Person (UKRP) appointment and authorisation letter support
- Full MHRA registration (DORS) filing and account lifecycle management
- Device classification, GMDN code selection and annual registration fee calculation
- Great Britain and Northern Ireland dual-pathway design and UK(NI) solutions
- Post-market surveillance (PMS) system setup, PMSR/PSUR preparation and vigilance reporting
- Serious incident and field safety corrective action (FSCA) emergency response
- UK regulatory change monitoring and compliance gap assessment
For tailored support with designated standards and conformity documentation for the UK market, contact GRZAN at info@grzanglobal.com.
Disclaimer
Prepared by GRZAN from publicly available regulation. It is provided for general information only and does not constitute legal advice. Legislation and official fees are subject to change by the competent authority.
About GRZAN
GRZAN (Global Regulatory Zone Access Navigator) — the global market-access navigator for medical devices and IVDs.
GRZAN is a specialist consultancy for medical device and IVD market access, providing end-to-end regulatory solutions across the product lifecycle and making international market entry simpler and faster.
Key figures. More than 25 wholly owned subsidiaries worldwide covering 50+ countries and regions; chosen by 100+ listed and leading Chinese device manufacturers, with 4,000+ successful cases; 12+ years in the sector and 200+ regulatory training sessions and seminars delivered.
What we do. Global market access: multi-country registration programmes, technical documentation, regulatory advice. Clinical evidence: clinical evaluation reports (CER), usability studies, overseas clinical investigations. Quality systems: ISO 13485, MDSAP, FDA QMSR and BGMP implementation and audit readiness. Authorised representative and licence-holder services across Southeast Asia, Latin America, the Middle East, Africa, Europe and North America.
Why GRZAN. A real operating entity, with the certificate held by the manufacturer: our direct overseas subsidiaries act as the compliant local holder, so the regulatory relationship stays clear and you keep control rather than being tied to a distributor. Direct access to the team: no time-zone gap, no language barrier, no cultural gap. Review points anticipated: we know what FDA 510(k), EU MDR, Southeast Asian, Latin American and Middle Eastern reviewers look for, which shortens timelines and reduces deficiency letters. Pathway planning: pre-decision analysis and risk assessment before you commit.
Every engagement rests on three commitments: efficiency through pre-submission review, certainty through a clear pathway, and stability through a licence-holder that stays in place.
Take your devices global with GRZAN
We work with manufacturers worldwide to open new markets with a clear regulatory pathway.
Contact us